Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) have announced the ‘Blue Knight Resident QuickFire Challenge: Accel
Janssen’s chief scientific officer and worldwide chairman Paul Stoffels has said he hopes the company’s coronavirus vaccine candidate will be available by “early next year” to millions of people
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh